These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 31651568)
1. Prostate cancer screening in Portugal: prevalence and perception of potential benefits and adverse effects. Braga R; Costa AR; Pina F; Moura-Ferreira P; Lunet N Eur J Cancer Prev; 2020 May; 29(3):248-251. PubMed ID: 31651568 [TBL] [Abstract][Full Text] [Related]
2. Screening for prostate cancer. Ilic D; Neuberger MM; Djulbegovic M; Dahm P Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794 [TBL] [Abstract][Full Text] [Related]
3. Occupation as a predictor of prostate cancer screening behaviour in Canada. Peters CE; Villeneuve PJ; Parent MÉ J Med Screen; 2020 Dec; 27(4):215-222. PubMed ID: 32000565 [TBL] [Abstract][Full Text] [Related]
4. Prevalence and characteristics of prostate cancer among participants of a community-based screening in Nigeria using serum prostate specific antigen and digital rectal examination. Ikuerowo SO; Omisanjo OA; Bioku MJ; Ajala MO; Mordi VP; Esho JO Pan Afr Med J; 2013; 15():129. PubMed ID: 24255735 [TBL] [Abstract][Full Text] [Related]
5. Cancer screening in Portugal: sex differences in prevalence, awareness of organized programmes and perception of benefits and adverse effects. Costa AR; Silva S; Moura-Ferreira P; Villaverde-Cabral M; Santos O; Carmo ID; Barros H; Lunet N Health Expect; 2017 Apr; 20(2):211-220. PubMed ID: 26914376 [TBL] [Abstract][Full Text] [Related]
6. Long-Term Outcome of a Single Intervention Population Based Prostate Cancer Screening Study. Lundgren PO; Kjellman A; Norming U; Gustafsson O J Urol; 2018 Jul; 200(1):82-88. PubMed ID: 29408619 [TBL] [Abstract][Full Text] [Related]
7. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134 [TBL] [Abstract][Full Text] [Related]
8. The Cuban Institute of Oncology and Radiobiology experience on the beliefs and opinions about digital rectal exam in urological patients. García Figueredo I; Pereda-Meira CM; Morejón Morales A; Correoso Braña K; Candia MN; Zarut Portillo P; Chappé Pacheco M Medwave; 2016 Jul; 16(6):e6501. PubMed ID: 27532102 [TBL] [Abstract][Full Text] [Related]
9. Prostate cancer screening: what do men know, think and do about their risk? exploring the opinions of men in an urban area in Lagos State, Nigeria: a mixed methods survey. Ugochukwu UV; Odukoya OO; Ajogwu A; Ojewola RW Pan Afr Med J; 2019; 34():168. PubMed ID: 32153708 [TBL] [Abstract][Full Text] [Related]
10. Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing. Shoag J; Halpern JA; Lee DJ; Mittal S; Ballman KV; Barbieri CE; Hu JC J Urol; 2016 Oct; 196(4):1047-52. PubMed ID: 27060052 [TBL] [Abstract][Full Text] [Related]
11. Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer. Halpern JA; Oromendia C; Shoag JE; Mittal S; Cosiano MF; Ballman KV; Vickers AJ; Hu JC J Urol; 2018 Apr; 199(4):947-953. PubMed ID: 29061540 [TBL] [Abstract][Full Text] [Related]
12. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399 [TBL] [Abstract][Full Text] [Related]
13. Why do men refuse or attend population-based screening for prostate cancer? Nijs HG; Essink-Bot ML; DeKoning HJ; Kirkels WJ; Schröder FH J Public Health Med; 2000 Sep; 22(3):312-6. PubMed ID: 11077903 [TBL] [Abstract][Full Text] [Related]
14. Prostate cancer detection by using digital rectal examination: contemporary practice patterns in the United States. Tourville EA; Nguyen MM Clin Genitourin Cancer; 2013 Sep; 11(3):263-9. PubMed ID: 23647941 [TBL] [Abstract][Full Text] [Related]
15. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P; Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643 [TBL] [Abstract][Full Text] [Related]
16. Baseline PSA testing for men in their 40s: testing in average-risk men aged 40 to 50 years should not be routinely performed. Carter HB Oncology (Williston Park); 2014 Feb; 28(2):155-6. PubMed ID: 24701706 [No Abstract] [Full Text] [Related]
17. Why do men refuse prostate cancer screening? Demographic analysis in Turkey. Ceber E; Cakir D; Ogce F; Simsir A; Cal C; Ozentürk G Asian Pac J Cancer Prev; 2008; 9(3):387-90. PubMed ID: 18990007 [TBL] [Abstract][Full Text] [Related]
18. A Pragmatic Approach to Prostate Cancer Screening. Tosoian JJ; Penson DF; Chinnaiyan AM JAMA; 2024 May; 331(17):1448-1450. PubMed ID: 38581253 [No Abstract] [Full Text] [Related]
19. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017 [TBL] [Abstract][Full Text] [Related]
20. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. Pinsky PF; Miller E; Prorok P; Grubb R; Crawford ED; Andriole G BJU Int; 2019 May; 123(5):854-860. PubMed ID: 30288918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]